Prof. Peled is an associate professor and the director of the Gene Therapy Institute, Hadassah Medical Center, Jerusalem where he directs a laboratory, focusing on the role of cytokines in hematopoietic stem cell biology, inflammation, and cancer. Prof. Peled has authored more than 110 publications and is listed as an inventor on over 200 patents. For the last 25 years he has studied the role of the chemokine receptor CXCR4 in stem cell mobilization and cancer and identified the CXCR4 antagonist Motixafortide as a potent anti-cancer and stem cell mobilization agent. His laboratory supported the development of this drug candidate from bench through phase I- III and FDA review. Prof. Peled is the founder of Biokine Therapeutics, AlonBio and SakuraBio.
He holds a Ph.D. from the Weizmann Institute of Science and is experience includes time spent as a post Dr. at Harvard Medical School and Millennium Pharmaceuticals Inc.
